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SUMMARY. Studies assessing the function of monocyte de-
rived dendritic cells (MD-DC) in individuals with hepatitis C
virus (HCV) infection have shown conﬂicting results.
Impaired MD-DC function in chronic HCV infection would
have important implications both for understanding the
pathogenesis of HCV infection and in the use of autologous
MD-DC in vaccination strategies. We determined the allo-
stimulatory capacity of MD-DC in the same patient before
and after HCV infection. Next, the phenotype, cytokine
production and allostimulatory function of immature and
mature MD-DC in individuals with persistent HCV infection
were compared directly with MD-DC from healthy individ-
uals. Finally, we assessed the ability of MD-DC to prime
autologous naı ¨ve peptide speciﬁc CD8+ T cells using HLA-
A2 class-I tetramers. DCs retained the same allostimulatory
capacity before and following the establishment of persistent
HCV infection. The surface phenotype and the amount of
interleukin (IL)-10 and IL-12(p70) produced during DC
maturation did not differ between HCV-infected individuals
and healthy controls. Mature DCs from HCV-infected indi-
viduals performed comparably in an allogeneic MLR com-
pared with healthy individuals. Mature MD-DC from HCV-
infected individuals stimulated the expansion of peptide
speciﬁc naı ¨ve CD8+ T cells. MD-DC from HCV-infected and
healthy individuals are phenotypically indistinguishable and
perform comparably in functional assays.
Keywords: dendritic cells, hepatitis C virus, monocytes,
ribavirin.
INTRODUCTION
Hepatitis C virus (HCV) infection is a major public health
issue, with 170 million people infected worldwide. The
majority of individuals who are infected develop persistent
infection [1], which may be associated with the development
of liver ﬁbrosis and hepatocellular carcinoma. During pri-
mary HCV infection, a vigorous multi-speciﬁc HCV-speciﬁc
CD8+ and CD4+ T-cell response can be detected [2,3].
However, these responses are not maintained in individuals
who develop persistent infection when HCV speciﬁc T-cell
responses become weak or undetectable ex vivo [2,4,5]. This
is in marked contrast to other persistent, but controlled
infections such as Epstein Barr Virus (EBV) and Cytomega-
lovirus (CMV) where strong and focused responses remain
detectable [6].
There are many possible reasons for the attenuated HCV-
speciﬁc T-cell response that is observed during persistent
HCV infection. These include T-cell exhaustion [7,8], viral
variation and escape [9,10], lack of CD4+ T-cell help and
induction of T-cell tolerance or deletion of activated HCV
speciﬁc T cells in the hepatic environment [11]. However,
it is also possible that antigen presenting cells infected with
hepatitis C virus fail to prime an appropriate T-cell response.
In support of the latter hypothesis, it has been suggested
that the stimulatory capacity of monocyte derived dendritic
cells (MD-DC) from patients with persistent HCV is impaired
[12–15], and that HCV structural and nonstructural pro-
teins may inhibit DC function [16–18]. Defects in MD-DC
phenotype and cytokine production [12–14] have also been
described, although the nature of these defects has been
inconsistent between studies. Furthermore, this ﬁnding has
fuelled the functional assessment of circulating myeloid and
plasmacytoid DCs in HCV infection, an area of current
controversy [19–22].
Abbreviations: HCV, hepatitis C virus; MD-DC, monocyte derived
dentritic cell; IVDU, intravenous drug user; TNF, tumour necrosis
factor.
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only for understanding the pathogenesis of HCV infection,
but also in the use of autologous MD-DC in vaccination
strategies. However, the ﬁnding that MD-DC in patients with
HCV are defective remains controversial. While some studies
have shown phenotypic or functional defects following MD-
DC maturation, these ﬁndings have not been supported in a
number of human [19,23] or chimpanzee studies [24,25].
In addition, patients with HCV infection do not exhibit global
immunosuppression in the absence of advanced liver disease,
as might be expected if HCV infection adversely affects MD-
DC function.
Therefore, in this study, we have revisited the question of
whether MD-DC function normally in patients with HCV
infection by assessing the phenotype, cytokine secretion and
stimulatory capacity of MD-DCs from patients with persistent
HCV. We have also analysed the ability of MD-DC to prime
naı ¨ve antigen speciﬁc T cells in vitro using an established
model of melan-A speciﬁc T-cell responsiveness. All experi-
ments were run in parallel and compared with MD-DC de-
rived from healthy donors. We have included only ribavirin
naı ¨ve patients, as recent studies have shown that ribavirin
has immunomodulatory properties both in vivo and in vitro
[26–28], and can attenuate DC function in vitro [29] and
in vivo [21].
Finally, as we demonstrate that there is a wide variation
in the magnitude of the stimulatory response between
individuals, as might be expected in an allogeneic MLR
reaction, we have assessed the stimulatory capacity of
MD-DC in a unique at risk population of intravenous
drug users (IVDU). This cohort allowed us to analyse the
functional capacity of MD-DC in the same individuals
before and following the establishment of persistent HCV
infection.
MATERIALS AND METHODS
Participants
With established persistent infection
Informed consent was obtained from each patient. The study
protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the ethics
committee of the John Radcliffe Hospital. Fifteen patients
with persistent HCV infection were consecutively recruited
from the out-patient clinic and studied prospectively. Each
patient was studied in parallel with a healthy control indi-
vidual without risk factors for the acquisition of viral hepa-
titis. We excluded patients with a prior history of any
treatment for HCV, including interferon (IFN)-alpha and⁄or
ribavirin treatment.
In all patients, HCV RNA was detectable by RT-PCR in the
serum on at least two consecutive occasions 6 months apart
(Roche v2.0 Amplicor assay; Roche Diagnostics Ltd). HCV
genotype was determined in those patients being considered
for therapy (Inno-Lipa HCV II, Innogenetics, Belgium).
Patient characteristics are shown in Table 1.
Patients studied before and after primary hepatitis C virus
infection
Intravenous drug users (IVDU) at risk for HCV infection
were identiﬁed in a prospective study of young IVDUs in
Table 1 Patient characteristics
Patient
(age⁄sex)
ALT
(10–45) Treated Genotype
Histology
(Ishak) MLR Phenotype
Cytokine
secretion
Melan-A
priming
Control
(age⁄sex)
HCV-1 (49⁄M) 120 No 3 6⁄6 (F) 8⁄18 (I) + + + ) HI-1 (39⁄M)
HCV-2 (40⁄M) 24 No ND 1⁄6 (F) 4⁄18 (I) + + + ) HI-2 (38⁄F)
HCV-3 (37⁄F) 34 No 1 2⁄6 (F) 4⁄18 (I) + + + ) HI-3 (34⁄F)
HCV-4 (47⁄M) 27 No 3 2⁄6 (F) 5⁄18 (I) + + + ) HI-4 (38⁄M)
HCV-5 (48⁄F) 41 No ND 1⁄6 (F) 2⁄18 (I) + )) ) HI-5 (36⁄M)
HCV-6 (44⁄F) 29 No 1 ND + + ))HI-6 (26⁄M)
HCV-7 (63⁄F) 22 No 5a 2⁄6 (F) 2⁄18 (I) + )) ) HI-7 (36⁄F)
HCV-8 (42⁄M) 61 No 1 1⁄6 (F) 3⁄18 (I) )) + ) HI-8 (37⁄F)
HCV-9 (38⁄M) 21 No 2b ND )) ) + HI-5 (36⁄M)
HCV-10 (47⁄F) 42 No 1a⁄1b 0⁄6 (F) 3⁄18 (I) )) ) + HI-8 (37⁄F)
HCV-11 (36⁄F) 49 No ND 1⁄6 (F) 2⁄18 (I) )) ) + HI-9 (36⁄F)
HCV-12 (41⁄F) 28 No 1 1⁄6 (F) 3⁄18 (I) )) ) + HI-9 (36⁄F)
HCV-13 (41⁄M) 61 No 1 1⁄6 (F) 3⁄18(I) )) ) + HI-8 (37⁄F)
13 patients were recruited consecutively from outpatients and paired with healthy controls for subsequent assays. +⁄)
indicates assays performed⁄not performed on each patient.
ALT, alanine transferase (normal range 10–45 IU⁄L), Histology – Ishak score; F, ﬁbrosis; I, inﬂammation; MLR, mixed
leukocyte reaction; ND, not done; IFN-a: 6-month course.
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220 E. Barnes et al.Baltimore, MD, as described previously and as approved by
the institutional review boards of the Johns Hopkins Schools
of Medicine and Hygiene and Public Health [30]. Partici-
pants eligible for the study were anti-HCV antibody negative,
between 15 and 30 years of age, and acknowledged use of
injection drugs. Eligible subjects consented to have blood
drawn for isolation of plasma and peripheral blood mono-
nuclear cell (PBMC) in a protocol designed for monthly fol-
low-up. At each visit, participants were provided counselling
to reduce the risks of drug use. Acute HCV infection was
identiﬁed by HCV antibody seroconversion, as described
previously [5]. All participants who acquired HCV infection
were offered treatment, but none of the subjects included in
this paper elected to be treated during the period of follow-up
reported in this study.
Allostimulatory capacity of MD-DC was determined using
MD-DC from before and following clearance or persistence in
seven subjects and, in one case, during the early phase of
infection as well as before and after infection. HCV clearance
was deﬁned as the presence of anti-HCV with HCV RNA
undetectable by the COBAS AMPLICOR qualitative assay in
serum or plasma specimens from ‡2 consecutive visits
obtained at least 300 days after initial detection of viremia.
Persistence wasdeﬁnedasthepersistent presenceofanti-HCV
with HCV RNA detectable by the qualitative or quantitative
COBAS AMPLICOR assay in serum or plasma specimens
obtained at least 300 days after initial viremia [30]. Of the
seven subjects, two cleared infection and ﬁve remained per-
sistently infected. All post-HCV infection MD-DC were derived
from PBMC acquired at least 300 days after infection. One
subject who ultimately cleared his HCV infection also had
MD-DC derived from PBMC acquired 8 months from onset of
viremia, while still HCV RNA positive, labelled his viremic
specimen. Five of the subjects were men, two were women,
threewere Caucasian,three wereAfrican-American, onewas
a Native American and the mean age at seroconversion was
26 years (range 22–29 years). They were all infected with
genotype 1 HCV. All patients were seronegative for HIV by
enzyme-linked immunosorbent assay.
Generation of immature dendritic cells
PBMC were isolated by centrifugation on Fycoll. To exclude
the possibility that functional defects of MDDC in HCV
infection is dependent on the method of generating MD-DC,
we used two different techniques.
For the Oxford cohort with chronic HCV infection,
monocytes were puriﬁed using anti-CD14 conjugated mag-
netic microbeads (Miltenyi Biotech, Bergisch Gladbach,
Germany). Immature DC were generated by culturing
monocytes in RPMI-10% endotoxin low fecal calfserum
(FCS) (Invitrogen), supplemented with pen-strep, 2 mM
L-glutamine, 1% nonessential aminoacids, 1% pyruvate,
5 · 10
)5 m 2-mercaptoethanol (Sigma, UK), granuolocyte-
macrophage colony-stimulating factor (50 ng⁄mL; Leuco-
max, Schering-Plough, UK) and IL-4 (250 IU⁄L; PeproTech,
UK) for 6 days. DCs were cultured in 6-well plates at a
concentration of 400 000 DCs⁄mL medium.
For the Baltimore cohort, monocytes were puriﬁed by
isolation of adherent cells after plating on a 6-well plate.
Immature DCs were generated by culturing monocytes in
Aim V media (Invitrogen) supplemented 2 mm l-glutamine,
GMCSF (800 IU⁄mL; R&D Systems) and IL-4 (800 IU⁄mL;
R&D Systems) at 37  C under 5% CO2 for 6 days with
replacement of 0.75 mL of Aim-V media with 600 IU each of
GMCSF and IL-4 on days 3 and 5.
Maturation of immature dendritic cells
Tumour necrosis factor (TNF)-a was used as the maturation
stimulus in many of the previous studies assessing allo-
stimulatory capacity [13,14,18]. To exclude the possibility
that the maturation defect in MD-DC previously described in
HCV infection is dependent on the nature of the maturation
stimulus used, we assessed two different maturation stimuli
in our assays. For the assessment of MD-DC in subjects with
chronic HCV infection immature DCs were stimulated with
dsRNA (Poly I:C, Sigma), 50 lg⁄mL for 36 h to generate
mature DCs. For the immature MD-DCs generated pre- and
post-HCV infection, maturation was achieved by incubation
with 10 ng⁄mL of TNF-a at 37  C under 5% CO2 for 24 h.
Phenotypic analysis
The phenotype of mature and immature DCs was evaluated
by surface staining with the following antibodies; Isotype
controls IgG1-FITC and IgG2a-PE (Dako), HLA class A, B, C-
RPE (clone W6⁄32; Dako), HLA-DP, DQ, DR-FITC (Pharm-
ingen), CD-83-FITC (Pharmingen) and CD-86-FITC (Dako).
7-AAD staining (Pharmingen) was used to exclude dead cells
from the analysis. Samples were analysed on a FACSCalibur
(Becton Dickinson) using cell quest software.
Cytokine determination
Cytokine produced by maturing DCs was determined in cell
supernatants 36 h after the addition of dsRNA in an ELISA,
using antibodies speciﬁc for IL-10 and IL-12(p70) according
to manufacturers instructions (Pharmingen).
Mixed leukocyte reaction
The stimulatory capacity of mature DCs from healthy control
and HCV-infected individuals or for the same individual pre-
and post-HCV infection was assessed via mixed leukocyte
reaction (MLR). Following DC maturation, DCs were har-
vested and irradiated (30 Gy). DCs were co-cultured in
increasing concentrations with allogeneic PBMC from a
healthy, HCV naı ¨ve donor. The same healthy donor PBMCs
were used in all experiments. After 5 days of co-culture,
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ated by the addition of 1 lCi [
3H] thymidine for 18 h. All
assays were performed in triplicate.
Melan-A peptides and tetramers
Melan-A peptide26–35 (ELAGIGILTV) (Sigma-Genosys) was
HPLC puriﬁed. This is an analogue of the melan-A 26–35
epitope with an improved HLA-A2 binding afﬁnity [31].
HLA-A2.1⁄melan-A peptide tetrameric complex was syn-
thesized as previously described [32]. Brieﬂy, modiﬁed HLA
A2.1 and b2-microglobulin were synthesized and puriﬁed
from a prokaryotic expression system and refolded in the
presence of melan-A peptide. Refolded complexes were
puriﬁed by FPLC and biotinylated, before combining with PE-
labelled streptavidin at a 4:1 molar ratio to form tetramers.
T-cell priming
Mature DCs were generated as above by the addition of
dsRNA. These were pulsed for 3 h with melan-A peptide,
1 lg⁄mL in serum free RPMI at 37  C. DCs from the same
individual pulsed with RPMI rather than peptide served as
negative controls. Cells were washed twice and incubated
with autologous PBMC at a 1:10 (DC:PBMC) ratio in RPMI
with 10% FCS. Human rIL-2 (10 IU⁄mL Proleukin) was
added after 5 days. Cells were expanded with 250 IU⁄mL IL-
2 at day 9 and harvested for staining with melan-A tetramer
at day 13. Precise timing was observed to allow accurate
comparisons of melan-A CD8+ T-cell expansions between
experiments. Cells were stained in PBS with melan-A tetra-
mer for 25 min at 37  C, washed and then incubated on ice
with 7-AAD (Pharmingen) to exclude dead cells from the
analysis in addition to CD8-FITC (Dako). Cells were analysed
on a FACSCalibur (Becton Dickinson) using cell quest soft-
ware.
Statistical analysis
Statistical analysis used the paired t-test. All analyses were
performed using GraphPad Prism
  3.0a for Macintosh. A P-
value <0.05 was considered signiﬁcant.
RESULTS
The phenotype of mature and immature dendritic cells in
hepatitis C virus-infected and healthy individuals
Monocyte derived dendritic cells were generated in parallel
from ﬁve HCV-infected individuals and ﬁve healthy controls
(Table 1). Immature MD-DC were matured with dsRNA. The
expression of class-I (HLA-A, -B, -C), class-II (HLA-DR, -DQ
and -DP), CD83 and CD86 before and following DC matu-
ration was determined. As previously described [33],
immature DCs expressed class-I, class-II and CD86 at inter-
mediate levels, but not CD83. These markers were
equally expressed in HCV-infected and healthy individuals
(Figs. 1a,b, upper panel). Furthermore, dsRNA-induced DC
maturation associated with the up-regulation of each of
these markers in both HCV-infected and healthy individuals
(Figs 1a,b, lower panel).
Cytokine production by dendritic cells from healthy and
hepatitis C virus-infected individuals
Supernatants were collected from maturing dendritic cell
cultures 36 h after the addition of dsRNA and the concen-
tration of IL-10 and IL-12(p70) was determined using an
ELISA in ﬁve individuals with HCV infection and compared
with ﬁve healthy controls (Table 1). While IL-10 was found
at a concentration 10-fold lower than IL-12(p70) and while
the amount of cytokine produced varied widely between
individuals as previously described [34], there was no sta-
tistical difference in the amount of IL-10 or IL-12 produced
by MD-DC from HCV-infected and healthy controls (Fig. 2).
The stimulatory capacity of dendritic cells from healthy
and hepatitis C virus-infected individuals
It has previously been reported that MD-DCs derived from
HCV-infected patients have a reduced stimulatory capacity.
We therefore assessed the stimulatory capacity of MD-DCs
from seven HCV-infected treatment naı ¨ve (Table 1; HCV-
1–7) patients and compared these with seven healthy
(Table 1; HI-1–7) individuals in parallel experiments. The
same responder (HI-10) PBMC was used in all assays. The
stimulatory capacity, using 10-fold increasing concentra-
tions of DCs (10, 10
2,1 0
3 and 10
4) in two representative
experiments from HCV-infected individuals (HCV-1, -6,) and
the paired healthy controls (HI-1, -6,) is shown (Fig. 3a).
Overall analysis (Fig. 3b) where the stimulatory capacity of
DCs is plotted against the stimulatory capacity of the paired
control at each DC concentration shows that there is no
signiﬁcant difference in the stimulatory capacity of DCs from
HCV and healthy controls. Regression analysis slope = 0.9
(95% conﬁdence intervals 0.74–1.03).
The stimulatory capacity of monocyte derived dendritic
cells in at risk individuals before, during and after infection
with hepatitis C virus infection
Although there was no difference in the stimulatory capacity
of MD-DC in HCV-infected individuals compared with heal-
thy controls, there was a marked variation in the allostim-
ulatory response between individuals that did not depend on
HCV infection status. To control for host variation, we as-
sessed a cohort of patients at risk for acquiring HCV infec-
tion, before acute infection and after the establishment of
persistent HCV infection (Fig. 4a; Subjects S7, S9, S13, S17
and S21) or clearance of HCV (Fig. 4b; Subjects S18 and
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222 E. Barnes et al.S63). In subject S18, who eventually cleared HCV, we also
assessed the stimulatory capacity of DCs generated from
PBMC acquired during early HCV infection, while still HCV
RNA positive. The same responder PBMCs were used in all
assays. We observed that the stimulatory capacity of MD-DC
prior to HCV infection was maintained throughout and
following HCV infection irrespective of the outcome of
infection. Once again, wide variation in stimulatory capacity
was observed between individuals, but not in the same host
before and after HCV infection.
Priming of naı ¨ve melan-A speciﬁc CD8+ T cells by
dendritic cells derived from healthy and hepatitis
C virus-infected individuals
Melan-A tetramer+ cells are detectable in the peripheral
blood of many healthy donors, typically at a frequency of less
than 0.07% CD8+ T cells [35]. These cells are antigen
inexperienced as conﬁrmed by multiple techniques [35–37].
Consistent with these ﬁndings, nonprofessional antigen
presenting cells expand melan-A speciﬁc CD8+ naı ¨ve T cells
only when pulsed with very high concentrations of peptide
(100 lg⁄mL), whereas melan-A peptide pulsed MD-DCs de-
rived from healthy individuals induce greater expansions
and require a low concentration of melan-A peptide
(1 ng⁄mL) [38]. We assessed the ability of DCs from HCV-
infected individuals, pulsed with low concentrations of mel-
an-A peptide, to prime a naı ¨ve T-cell population. Each
experiment was run in parallel with DCs obtained from
healthy individuals. Three representative experiments are
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Fig. 1 The phenotypic characteristics
of immature and mature DCs in HCV
infected and healthy individuals. The
expression (mean ﬂuorescence inten-
sity–MFI) of HLA class I, HLA class II,
CD 86 and CD83 on immature (bold
line) and dsRNA matured (dotted line)
MD-DCs from a representative HCV
infected individual (HCV-2) and a
healthy control individual is shown
(HI-2) (A). The expression of these
markers on MD-DCs is compared
between healthy and HCV infected
individuals on both immature (B, upper
panel) and mature (B, lower panel)
MD-DCs. The table inserts give the
MFI ± standard error and P values for
each marker.
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Fig. 2 Cytokine production by maturing DCs derived from
HCV infected and healthy individuals. Culture supernatants
were sampled 36 h after the addition of dsRNA to immature
DCs derived from HCV and healthy individuals. IL-10 and
IL-12(p70) concentrations were measured by ELISA.
  2007 The Authors
Journal compilation   2007 Blackwell Publishing Ltd
MDDC function before and after persistent HCV infection 223shown (Fig. 5). DCs from both HCV-infected and healthy
individuals were able to prime naı ¨ve melan-A speciﬁc T cells.
Melan-A speciﬁc T cells could be expanded in 2⁄3 healthy
and 3⁄5 HCV individuals tested [not signiﬁcant (P = 0.99)
Fishers exact test]. The frequency of melan-A speciﬁc T cells
that were primed using DCs from HCV-infected individuals
(median 0.1% CD8+ T cells, range 0–0.73%) was not sig-
niﬁcantly different from the frequencies obtained using DCs
from healthy individuals (median 0.16%, range 0–1.2%).
In all cases, the frequencies of melan-A speciﬁc T cells
co-cultured with autologous DCs that were not pulsed with
melan-A peptide were <0.02% CD8+ T cells.
DISCUSSION
In this study, we show that MD-DCs derived from HCV-in-
fected individuals are phenotypically and functionally
indistinguishable from healthy controls. Furthermore, the
stimulatory capacity of MD-DC is maintained before, during
early and after the establishment of persistent HCV infection
within the same individual.
The observation that T–cell responses are attenuated
during persistent HCV infection has prompted investigation
into the effects of HCV infection on DC function, cells which
are crucially involved in inducing an effective, appropriate
T-cell response. However, the ﬁnding that MD-DC are func-
tionally impaired in HCV infection is highly controversial
[12–16,19,23–25]. The search for the mechanism behind
this observation has also produced conﬂicting data. For
example, it has been reported that the up-regulation of the
phenotypic markers (CD86, class II and CD83) associated
with DC maturation in HCV-infected individuals is normal
[13] despite impaired allostimulatory capacity. However,
it has also been reported that the expression of CD86 is not
Linear regression;  slope = 0.9 
(95% CI 0.74–1.03)
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Fig. 3 The stimulatory capacity of DCs derived from HCV and healthy individuals. The stimulatory capacity of DCs derived
from HCV and healthy individuals was assessed in paired assays run in parallel. Following irradiation, dsRNA matured DCs at
10-fold increasing concentrations (0–10
4) were co-cultured with allogeneic PBMC (5 · 10
4). T-cell proliferation was deter-
mined on day 6 of culture following 18 h incubation with
3H thymidine (c.p.m. = counts per minute). The results are
expressed as mean ± SD of wells in triplicates. The same responder PBMCs from a healthy individual were used in all
experiments. Two representative experiments are shown (A). In an overall analysis (B),
3H thymidine incorporation using DCs
from each HCV infected patient is plotted against
3H thymidine incorporation for the paired healthy control (HCV⁄ HI-1–7) at
each DC concentration (10, 10
2,10
3 and 10
4). Linear regression analysis; slope = 0.9 (95% conﬁdence interval (CI) 0.735–
1.025).
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224 E. Barnes et al.up-regulated [12], and that the expression of CD83 and class
II are not up-regulated, while CD86 is up-regulated [14]. The
assessment of IL-12(p70) production and the role of cyto-
kines in restoring the allostimulatory defect is similarly
conﬂicting [12,13].
Previous studies have suggested that impaired DC function
is because of infection of DC with HCV. The ﬁnding in a
single patient, that MD-DC are productively infected [13]
means that the precursor monocytes must have also been
infected. However, a previous study [39] of 10 patients failed
to demonstrate HCV-negative strands that are associated
with viral replication in the monocyte population in any of
these individuals and HCV-negative strands were detected in
the DC population in a single individual only. More recently,
negative strand HCV RNA as evidence of HCV replication
could be detected in blood DCs in only 3⁄24 individuals with
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Fig. 4 The stimulatory capacity of DCs
derived from individuals before and
following HCV infection. The stimula-
tory capacity of DCs was determined
before and >300 days following HCV
infection and also during acute infec-
tion in subject 18. Patients S7, S9, S13,
S17 and S21 developed persistent
infection (A) while patients S18 and
S63 spontaneously cleared virus (B).
Following irradiation, matured DCs at
increasing concentrations were co-cul-
tured with allogeneic PBMC (2 · 10
5).
T-cell proliferation was determined on
day 6 of culture following 18 h incu-
bation with
3H Thymidine
(c.p.m. = counts per minute). The
results are expressed as mean ± SD of
wells in triplicates. The same responder
PBMCs from a healthy individual were
used in all experiments.
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infection may occur, it is a rare event which cannot readily
account for the attenuation of T-cell responses observed in
the vast majority of patients with persistent HCV infection.
Although productive infection of DCs and impaired DC
function has been reported with human immunodeﬁciency
virus [41–44] and with measles virus [45–47], both of these
viruses are associated with profound clinical immune de-
fects. It is hard to reconcile the reported general allostimu-
latory defect in individuals with persistent HCV infection
with the clinical observation that HCV-infected individuals
are not overtly immunosuppressed after over a decade of
follow-up. Our observations that DCs derived from patients
with HCV infection function normally are consistent with
this broad clinical picture.
It is possible that the inclusion of patients taking ribavirin
[13] either at the time of study or in the past [14] may have
accounted at least in part for inconsistencies between studies.
The pharmacokinetic properties of ribavirin include high
intracellularlevelswithaprolongedhalf-lifeinvivo(morethan
6 months) [48]. It is now clear that ribavirin has immuno-
modulatory properties both in vivo and in vitro [26–28], and
can attenuate DC function in vitro [29] and in vivo [21].
It is also possible that study differences may be accounted
for by patient cohorts with different amount of liver
inﬂammation⁄ﬁbrosis and that the alteration in DC function
described is induced in part by liver pathology rather than by
HCV. Notably, the majority of patients in our study had mild
liver disease.
Another possible explanation for discrepancies between
previous studies is that differences are reﬂective of host dif-
ferences rather than the effects of HCV infection. Consistent
with this, our results show that there is signiﬁcant inter-
individual variation in the stimulatory capacity of DCs using
an allogenic MLR. However, the allostimulatory capacity of
MD-DC from patients before and after HCV infection does not
differ in the same host, showing that this variation is not a
consequence of HCV infection.
Using the melan-A model to assess the ability of DCs to
prime a naı ¨ve antigen speciﬁc population [38,49], we show
that individuals with persistent HCV infection are able to
prime a naı ¨ve T-cell response at least in vitro. We accept the
limitations of this model, which may not translate to the
priming environment in vivo and which does not necessarily
represent the situation in primary HCV infection. However,
vigorous and multi-speciﬁc T-cell responses are detected
during primary infection regardless of outcome at a time
when HCV viral loads are very high [2,3,50]. In keeping
with our in vitro observations, in this situation, HCV-speciﬁc
T-cell responses are clearly primed in vivo. However, it re-
mains possible that a subtle defect in priming during primary
infection results in an HCV-speciﬁc T-cell response that is not
maintained or is not optimally functional.
The results from our study which demonstrate that DCs
from HCV-infected patients function comparably with heal-
thy controls, the lack of a common DC phenotype in previ-
ously published reports of patients with chronic HCV, and
the fact that patients with a decade of HCV infection in the
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Fig. 5 The efﬁcient expansion of melan-
A speciﬁc CD8+ T cells from healthy
and HCV infected individuals. In three
representative paired, controlled experi-
ments, dsRNA matured MD-DCs from
healthy (left hand panel; HI-5, -8, -9)
and HCV infected (right hand panel;
HCV-9, -10, -11) individuals were
pulsed with 1 lg ⁄mL melan-A26-35
peptide or RPMI medium, washed thor-
oughly and then incubated with autol-
ogous PBMC at a ratio of 1DC: 10
PBMCs. After 13 days, cultures were
stained with melan-A tetramer-PE, CD
8-FITC and 7-AAD. DCs are gated on
the live population. % tetramer+⁄CD8+
T cells is given in each FACS plot.
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226 E. Barnes et al.absence of severe liver disease are immunocompetent sug-
gests that DC function in HCV warrants continued evalua-
tion. Future studies that concentrate on DC function during
primary infection, intra-hepatic DC function and the role of
circulating myeloid and plasmacytoid DCs, will be particu-
larly informative.
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